1. INTRODUCTION
===============

The glutamate hypothesis is one of the prevailing hypotheses for the pathophysiology of schizophrenia \[[@R1]\]. Also, a recent clinical study showed that LY379268, an agonist of metabotropic glutamate 2/3 receptor (mGluR2/3) that is involved in group II mGluR regulate glutamate neurotransmission through a presynaptic negative regulatory mechanism, has an effect on psychotic symptoms in schizophrenia almost equivalent to that of olanzapine \[[@R1]\].

Several investigations have suggested that metabotropic glutamate 3 receptor (mGluR3) gene has an association with schizophrenia \[[@R2]-[@R4]\]. Since the symptoms of methamphetamine-induced psychosis are similar to those of paranoid type schizophrenia \[[@R5]\], it would seem that the mGluR3 gene (*GRM3*) is a good candidate gene for the pathogenesis of methamphetamine-induced psychosis. To evaluate the association between *GRM3* and methamphetamine-induced psychosis, we conducted a case-control study of Japanese samples (181 methamphetamine-induced psychosis patients and 232 controls). The mGluR3 gene (*GRM3* OMIM \*601115, 6 exons in a genomic region spanning 221.763Kb) is at 7q21. We selected rs6465084 in *GRM3*, which is reported to be associated with prefrontal brain functioning. Rs6465084 has been found to be associated with decreased verbal list learning and verbal fluency \[[@R3]\]. In addition, Egan and colleagues reported that the rs6465084 A allele predicted decreased levels of *N*-acetylaspartate in the prefrontal cortex in an *in vivo*study, and suggested that the rs6465084 A allele reduced tissue glutamate levels and synaptic abundance \[[@R3]\].

2. MATERIALS AND METHODS
========================

2.1. Subjects
-------------

The subjects in the association analysis were 181 methamphetamine- induced psychosis patients(155 males and 26females; mean age33.3 ± 11.4) and 232 controls (187males and 45females; mean age36.4 ± 11.3). All subjects were unrelated to each other, ethnically Japanese, and lived in the central area of Japan. The patients were diagnosed according to DSM-IV criteria with consensus of at least two experienced psychiatrists on the basis of unstructured interviews and a review of medical records. One hundred thirty-seven subjects with METH- induced psychosis also had dependence on drugs other than METH. Subjects with METH-induced psychosis were excluded if they had a clinical diagnosis of psychotic disorder, mood disorder, anxiety disorder or eating disorder. More detailed characterizations of these subjects have been published elsewhere \[[@R6]-[@R8]\]. All healthy controls were also psychiatrically screened based on unstructured interviews including current and past psychiatric history. None had severe medical complications such as cirrhosis, renal failure, heart failure or other Axis-I disorders according to DSM-IV. No structured methods were used to assess psychiatric symptoms in the controls, which included hospital staff, their families and medical students.

The study was described to subjects and written informed consent was obtained from each. This study was approved by the Ethics Committee at Fujita Health University, Nagoya University School of Medicine and and each participating member of the Institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA).

2.2. SNP Selection
------------------

We selected rs6465084 in *GRM3*, which is reported to be associated with prefrontal brain functioning, for the following association analysis.

2.3. SNP Genotyping
-------------------

SNP genotyping was done using TaqMan assays (Applied Biosystems) \[[@R9]\].

2.4. Statistical Analysis
-------------------------

Genotype deviation from the Hardy-Weinberg equilibrium (HWE) was evaluated with the chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan).

Marker-trait association analysis was used to evaluate allele- and genotype-wise association with the chi-square test (SAS/Genetics, release 8.2, SAS Japan Inc, Tokyo, Japan). To control inflation of the type I error rate, we used Bonferroni's correction. Power calculation was performed using a statistical program prepared by Purcell *et al.*

The significant level for all statistical tests was 0.05.

3. RESULTS
==========

Rs6465084 is in HWE. We detected no association between rs6465084 in *GRM3* and METH-induced psychosis in the allele/genotype-wise analysis (Table **[1](#T1){ref-type="table"}**).

4. DISCUSSION
=============

We performed an association study of rs6465084 in *GRM3* and METH- induced psychosis in the Japanese population. Although, we recently found an association between *GRM2* and METH- induced psychosis in the Japanese population \[[@R10]\], in the present study we detected no association between *GRM3* with METH-induced psychosis.

Egan and colleagues reported that the rs6465084 A allele predicted decreased levels of *N*-acetylaspartate in the prefrontal cortex in an *in vivo*study, and suggested that the rs6465084 A allele reduced tissue glutamate levels and synaptic abundance \[[@R3]\]. This influence of *GRM3*on prefrontal cortex and cognitive function suggests that abnormalities in glutamate neurotransmission may be involved in the pathophysiology of METH- induced psychosis. However, we did not detect an association between *GRM3* and METH-induced psychosis. We designed the present study based on common disease--common variants hypothesis (CD--CV hypothesis) \[[@R11]\]. In addition, we selected only one SNP in *GRM3*. A recent study has showed an association between common diseases such as schizophrenia and rare variants. If the genetic background of METH-induced psychosis is accurately described by the common disease-rare variants hypothesis, further investigation such as medical resequencing using larger samples will be required \[[@R8],[@R12]-[@R17]\].

There are a few limitations in this study. First, the lack of association may be due to biased samples, such as small sample sizes. Second, we selected only one SNP in *GRM3*. To overcome these limitations, it will be necessary conduct a replication study using gene based association analysis and larger samples.

5. CONCLUSION
=============

Our results suggest that rs6465084 in *GRM3* does might not play a role in the pathophysiology of METH-induced psychosis in the Japanese population. However, our results have limitations and replication study using gene-based association analysis and larger samples will be required.

###### 

Association Analysis of *GRM3* with MAP with Psychosis

  SNP         Phenotype^[a](#T1FN1){ref-type="table-fn"}^   MAF^[b](#T1FN2){ref-type="table-fn"}^   N     Genotype Distribution   *P*-Value^[c](#T1FN3){ref-type="table-fn"}^                       
  ----------- --------------------------------------------- --------------------------------------- ----- ----------------------- --------------------------------------------- --- ------- ------- -------
  rs6465084   Controls                                      0.0926                                  232   193                     35                                            4   0.117   0.153   0.941
  A\>G        MAP with psychosis                            0.0911                                  181   148                     33                                            0   0.177           

MAP with psychosis: methanphetamine use disorder with psychosis

MAF: major allele frequency

Hardy-Weinberg equilibrium.
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